Merck's Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20
Shots:
- The P-III KEYNOTE-177 study involves assessing of Keytruda (200mg IV on Day 1 of each 3wks. cycle for up to 35cycles) vs SOC CT (mFOLFOX6 or FOLFIRI- with/ out bevacizumab or cetuximabin) in 307 patients with 1L MSI-H or dMMR metastatic colorectal cancer
- Results: PFS (16.5 vs 8.2mos.); @2yrs. PFS rate (48% vs 19%); ORR (43.8% vs 33.1%); CR (11.1% vs 3.9%); PR (32.7% vs 29.2%); durable responses lasting at least 2yrs. (83% vs 35%)- presented on May 31- 2020 at ASCO20
- Additionally- Merck also presented data from two studies (KEYNOTE-524/Study 116 and KEYNOTE-146/Study 111) evaluating Keytruda + Lenvima in patients with unresectable HCC with no prior systemic therapy and with metastatic ccRCC who progressed following immune checkpoint inhibitor therapy- respectively. The studies demonstrated a meaningful improvement in ORR
Click here to read full press release/ article
Ref: Merck | Image: Merck
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com